By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a

At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.


Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

Key Statistics

Ownership: Private

Web Site: Janssen R&D


Company News
Janssen R&D Release: New Phase 3 Study Findings Show STELARA Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn's Disease 5/24/2016 7:38:19 AM
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen (AMGN) 4/1/2016 6:02:13 AM
Janssen Research & Development Release: First Phase 3 Trial Of Daratumumab In Combination With Standard Therapy In Relapsed/Refractory Multiple Myeloma Meets Primary Endpoint In Planned Interim Analysis 3/30/2016 10:54:59 AM
Janssen Research & Development Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset 3/22/2016 8:03:28 AM
Janssen Research & Development, Genentech (RHHBY) Forge Clinical Trials Agreement 3/22/2016 6:34:02 AM
Janssen Research & Development Announces The Initiation Of Two Studies Evaluating Daratumumab (DARZALEX) And Atezolizumab In Multiple Myeloma And Solid Tumor 3/22/2016 6:21:19 AM
Janssen Research & Development Release: STELARA Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy 3/18/2016 10:45:24 AM
Janssen Research & Development And Johnson & Johnson (JNJ) To Provide Webcast Presentation On The Janssen Oncology Hematologic Malignancy Portfolio 1/15/2016 8:21:43 AM
Janssen Research & Development Release: Ibrutinib (IMBRUVICA) Significantly Improved Progression-Free And Overall Survival Versus Chlorambucil In Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 12/7/2015 7:33:52 AM
Janssen Research & Development Release: Daratumumab (DARZALEX) Combined With Standard Treatment For Multiple Myeloma Produced Deep And Durable Responses In Relapsed Or Refractory Patients 12/7/2015 6:49:24 AM